CD55, a potential immunotherapeutic target for MYCN-amplified neuroblastoma

Neuro Oncol. 2022 Jun 1;24(6):886-887. doi: 10.1093/neuonc/noac020.

Authors

Hiroyuki Yoda^{1

2}, William A Weiss^{1

2

3}

Affiliations

¹ UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, USA.
² Department of Neurology, University of California, San Francisco, San Francisco, California, USA.
³ Departments of Neurology, Pediatrics, and Neurological Surgery, University of California, San Francisco, San Francisco, California, USA.

No abstract available

Publication types

Editorial
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
Comment

MeSH terms

Human Embryonic Stem Cells*
Humans
Immunotherapy
N-Myc Proto-Oncogene Protein / genetics
Neoplastic Stem Cells
Neural Crest
Neuroblastoma* / genetics
Neuroblastoma* / therapy
Transcription Factors

Substances

MYCN protein, human
N-Myc Proto-Oncogene Protein
Transcription Factors

Grants and funding